Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(8%)
Results Posted
100%(6 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_3
1
8%
Ph early_phase_1
1
8%
Ph phase_4
2
15%
Ph phase_2
4
31%
Ph phase_1
3
23%

Phase Distribution

4

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(6)
Terminated(3)
Other(1)

Detailed Status

Completed6
Terminated2
Not yet recruiting2
Withdrawn1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (9.1%)
Phase 13 (27.3%)
Phase 24 (36.4%)
Phase 31 (9.1%)
Phase 42 (18.2%)

Trials by Status

completed646%
withdrawn18%
unknown18%
recruiting18%
terminated215%
not_yet_recruiting215%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials
NCT07792096Phase 3

An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa

Not Yet Recruiting
NCT04518228

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Terminated
NCT04535544Phase 2

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Completed
NCT07258251Phase 4

Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach

Not Yet Recruiting
NCT05550519Early Phase 1

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment

Withdrawn
NCT04585789Phase 2

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Completed
NCT04129554Phase 2

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed
NCT05423106Phase 1

A Single and Multiple Ascending Dose Study of JNJ-64457744

Terminated
NCT02984852Phase 1

Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

Completed
NCT05583006

Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B

Recruiting
NCT04667104Phase 2

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed
NCT02437110Phase 1

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT04034368Phase 4

A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13